Journal of Neuro-Oncology

, Volume 111, Issue 3, pp 347–353 | Cite as

A phase II trial of oral gimatecan for recurrent glioblastoma

  • Jethro Hu
  • Patrick Y. Wen
  • Lauren E. Abrey
  • Camilo E. Fadul
  • Jan Drappatz
  • Nadia Salem
  • Jeffrey G. Supko
  • Fred Hochberg
Clinical Study


Gimatecan is a lipophilic oral camptothecin analogue with preclinical activity in glioma models. We conducted a multicenter phase II trial to evaluate the efficacy of gimatecan in adults with recurrent glioblastoma. Eligibility criteria included ≤1 prior treatment for recurrent disease, age ≥18, Eastern Cooperative Oncology Group performance status 0–1, and normal organ function. Patients taking enzyme-inducing anti-seizure medications were excluded. Gimatecan 1.22 mg/m2 was given orally once daily for 5 consecutive days during each 28-day cycle. The primary endpoint was progression-free survival at 6 months. A Simon 2-stage optimal design was used in which 19 patients were evaluated in the 1st stage, with an additional 36 patients accrued if >4 patients in stage 1 achieved PFS at 6 months. 29 patients were enrolled in the study, with median age of 58 years (range, 25–77 years); 58.6 % female. All patients received prior surgery, radiation therapy, and at least one chemotherapy regimen. The daily dose was reduced to 1.0 mg/m2 after four of the first 10 patients experienced grade 4 hematologic toxicity. Treatment-related grade 3/4 toxicities included thrombocytopenia (17.2 %), leukopenia (17.2 %) and neutropenia (10.3 %). None of the 19 patients treated at 1.0 mg/m2/day experienced grade 4 hematologic toxicity. One patient had a partial radiographic response by modified Macdonald criteria. Only 3 patients (12 %) were progression-free at 6 months. Median time to progression was 12.0 weeks (7.0, 17.0).Treatment with gimatecan 1.0 mg/m2/day for 5 days, repeated every 28-days showed minimal efficacy.


Gimatecan Glioblastoma Clinical trial Camptothecin Brain tumor Glioma 



Grant support from Sigma-Tau Research.

Conflict of interest

N. Salem is employed by Sigma-Tau.

Ethical standards

This study complies with the current laws of the United States of America.


  1. 1.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Groups EOfRaToCBTaR, Group NCIoCCT. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  2. 2.
    Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174PubMedCrossRefGoogle Scholar
  3. 3.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740PubMedCrossRefGoogle Scholar
  4. 4.
    Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–661PubMedGoogle Scholar
  5. 5.
    Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–1525PubMedGoogle Scholar
  6. 6.
    Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, Consortium NABT (2006) A phase II trial of irinotecan (cpt-11) in patients with recurrent malignant glioma: a north american brain tumor consortium study. Neuro–Oncol 8:189–193PubMedGoogle Scholar
  7. 7.
    Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S, Consortium NC (2004) Phase II study of weekly irinotecan in adults with recurrent malignant glioma: final report of nabtt 97–11. Neuro–Oncol 6:21–27PubMedGoogle Scholar
  8. 8.
    Lopez KA, Tannenbaum AM, Assanah MC, Linskey K, Yun J, Kangarlu A, Gil OD, Canoll P, Bruce JN (2011) Convection-enhanced delivery of topotecan into a pdgf-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res 71:3963–3971PubMedCrossRefGoogle Scholar
  9. 9.
    De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F (2001) Potent antitumor activity and improved pharmacological profile of st1481, a novel 7-substituted camptothecin. Cancer Res 61:7189–7195PubMedGoogle Scholar
  10. 10.
    Hsiang YH, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase i-dna cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077–5082PubMedGoogle Scholar
  11. 11.
    De Cesare M, Pratesi G, Veneroni S, Bergottini R, Zunino F (2004) Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clin Cancer Res 10:7357–7364PubMedCrossRefGoogle Scholar
  12. 12.
    Zhu AX, Ready N, Clark JW, Safran H, Amato A, Salem N, Pace S, He X, Zvereva N, Lynch TJ, Ryan DP, Supko JG (2009) Phase i and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res 15:374–381PubMedCrossRefGoogle Scholar
  13. 13.
    Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D’Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L (2007) Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (st1481) in patients with advanced solid tumors. Ann Oncol 18:561–568PubMedCrossRefGoogle Scholar
  14. 14.
    Boni C, Gamucci T, Bonetti A, Bisagni G, Dall’o’ E, Zanna C, Marsoni S, Sessa C, Azienda Ospedaliera S, Nuova M, Emilia R (2004) A phase II study of the novel oral camptothecin st1481 in pretreated metastatic colorectal cancer (crc). J Clin Onco 3684Google Scholar
  15. 15.
    Mariani P, Moliterni A, Da Prada G, Hess D, Gamucci T, Zaniboni A, Malossi A, Barbieri P, Marsoni S, Gianni L (2006) A phase II trial of the novel oral camptothecin gimatecan (g) in women with anthracycline (a) and taxane (t) pre-treated advanced breast cancer. J Clin Oncol 662Google Scholar
  16. 16.
    Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, Katsaròs D, Lhommé C, Lissoni AA, Vermorken JB, du Bois A, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, Guastalla JP (2010) Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol 21:759–765PubMedCrossRefGoogle Scholar
  17. 17.
    Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG (2008) Consortium NAtBTTC. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro–Oncol 10:608–616PubMedGoogle Scholar
  18. 18.
    Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF (1998) Phenytoin alters the disposition of topotecan and n-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4:783–789PubMedGoogle Scholar
  19. 19.
    Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S (2003) Phase i clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9:2940–2949PubMedGoogle Scholar
  20. 20.
    Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase ii studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  21. 21.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  22. 22.
    Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase ii clinical trials. J Clin Oncol 17:2572–2578PubMedGoogle Scholar
  23. 23.
    Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD, Consortium NABT (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro–Oncol 10:162–170PubMedGoogle Scholar
  24. 24.
    Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J (1997) Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76:952–962PubMedCrossRefGoogle Scholar
  25. 25.
    Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, Zunino F (2003) Antiangiogenic effects of the novel camptothecin st1481 (gimatecan) in human tumor xenografts. Mol Cancer Res 1:863–870PubMedGoogle Scholar
  26. 26.
    Smith LM, Willmore E, Austin CA, Curtin NJ (2005) The novel poly(adp-ribose) polymerase inhibitor, ag14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res 11:8449–8457PubMedCrossRefGoogle Scholar
  27. 27.
    Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK (1990) Development of a stable camptothecin-resistant subline of p388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471–480PubMedGoogle Scholar
  28. 28.
    Vassal G, Hamelin N, Opolon P, Versace R, Geoerger B (2008) The topoisomerase I inhibitor gimatecan exhibits synergistic antitumor activity in combination with imatinib mesylate and everolimus against malignant glioma xenografts. 2073Google Scholar
  29. 29.
    Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the uk mrc focus trial. J Clin Oncol 26:2690–2698PubMedCrossRefGoogle Scholar
  30. 30.
    Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N (2007) Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 17:76–82PubMedCrossRefGoogle Scholar
  31. 31.
    Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, Nussenzweig A, Aladjem MI, Bonner WM, Pommier Y (2003) Phosphorylation of histone h2ax and activation of mre11, rad50, and nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA-topoisomerase I cleavage complexes. J Biol Chem 278:20303–20312PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Jethro Hu
    • 1
  • Patrick Y. Wen
    • 2
  • Lauren E. Abrey
    • 3
  • Camilo E. Fadul
    • 4
  • Jan Drappatz
    • 5
  • Nadia Salem
    • 6
  • Jeffrey G. Supko
    • 7
  • Fred Hochberg
    • 8
  1. 1.Johnnie L. Cochran Jr. Brain Tumor CenterLos AngelesUSA
  2. 2.Center For Neuro-Oncology, Dana-Farber Cancer InstituteBostonUSA
  3. 3.Department of Neurology, University of ZurichZurichSwitzerland
  4. 4.Norris Cotton Cancer Center, Dartmouth Hitchcock Medical CenterLebanonUSA
  5. 5.UPMC Cancer PavilionPittsburghUSA
  6. 6.Sigma-Tau Pharmaceuticals Inc.GaithersburgUSA
  7. 7.Clinical Pharmacology LaboratoryMassachusetts General HospitalBostonUSA
  8. 8.Stephen E. & Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer CenterHarvard Medical SchoolBostonUSA

Personalised recommendations